NeuroOne Medical Technologies Corporation
NMTC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NMTC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NMTC
NeuroOne Medical Technologies Corporation is a medical technology company developing and commercializing thin film electrode technology for brain-related conditions, pain management, and drug delivery, with a focus on diagnostic, ablation, and stimulation applications.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial · 1 catalyst for NeuroOne Medical Technologies Corporation.
NeuroOne Medical Technologies Corporation is a medical technology company developing and commercializing thin film electrode technology for brain-related conditions, pain management, and drug delivery, with a focus on diagnostic, ablation, and stimulation applications.
- NeuroOne focuses on diagnostic, ablation, and deep brain stimulation technology for brain conditions such as epilepsy and Parkinson's disease, as well as pain management and drug delivery [sec_mda · as of 2026-08-13].
- The company commercializes thin film electrode technology for continuous EEG (cEEG) and stereoelectroencephalography (sEEG), spinal cord stimulation, and brain stimulation [sec_mda · as of 2026-08-13].
- As of June 30, 2026, NeuroOne reported cash and equivalents of $2.0M, total revenue of $2.0M, and a net loss of -$2.0M [sec].
- The company has generated revenue from sales of its Evo Cortical, Evo sEEG, OneRF Ablation System, and OneRF TN Ablation System, as well as milestone payments from collaboration and distribution agreements [sec_mda · as of 2026-08-13].
- Management has expressed substantial doubt about the company's ability to continue as a going concern, with cash and equivalents of approximately $3.6 million as of December 31, 2025, potentially insufficient to fund operations for twelve months [sec_mda · as of 2026-02-17].
What works
- NeuroOne has begun generating revenue from multiple commercial products, including Evo Cortical, Evo sEEG, and OneRF Ablation Systems, indicating initial market traction [sec_mda · as of 2026-08-13].
- The company's thin film electrode technology addresses multiple large markets: brain-related conditions (epilepsy, Parkinson's), pain management, and drug delivery, providing diversification [sec_mda · as of 2026-08-13].
- Strategic partnerships and distribution agreements provide milestone payments and potential for broader commercialization [sec_mda · as of 2026-08-13].
What to weigh
- NeuroOne has a history of net losses and negative cash flow from operations, with an accumulated deficit and reliance on external financing [sec_mda · as of 2026-08-13].
- Management has identified substantial doubt about the company's ability to continue as a going concern, with cash reserves potentially insufficient to fund operations for the next twelve months [sec_mda · as of 2026-02-17].
- The company faces risks related to maintaining Nasdaq listing compliance, supply chain disruptions, and market acceptance of its technology [sec · filed 2025-10-06].
- Expenses are expected to increase substantially as the company continues product development, clinical trials, and commercialization, putting further pressure on liquidity [sec_mda · as of 2026-02-17].
From the filings
Quoted directly from source documents.
NeuroOne's focus areas include brain conditions, pain management, and drug delivery.
“We are a medical technology company focused on (i) diagnostic, ablation and deep brain stimulation technology for brain related conditions such as epilepsy and Parkinson's disease; (ii) ablation and stimulation for pain management throughout the body; and (iii) drug delivery to the brain including diagnostic and stimulation capabilities.”
SEC MD&A · August 13, 2026
The company has generated revenue from product sales and milestone payments.
“While we have begun to generate revenue from the sale of our Evo Cortical, Evo sEEG, OneRF Ablation System, and OneRF TN Ablation System, and through milestone and other payments from our current collaboration and distribution ar”
SEC MD&A · August 13, 2026
Management has substantial doubt about the company's ability to continue as a going concern.
“Management has noted the existence of substantial doubt about our ability to continue as a going concern.”
SEC MD&A · February 17, 2026
Cash and equivalents were approximately $3.6 million as of December 31, 2025.
“At December 31, 2025, we had cash and cash equivalents in the aggregate of approximately $3.6 million.”
SEC MD&A · February 17, 2026
Catalyst timeline
- 2031-12-01 · Phase3_Topline — Topline results from a randomized study of resection and GammaTile followed by concurrent external beam radiation therapy are expected.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Management has substantial doubt about the company's ability to continue as a going concern due to insufficient cash to fund operations for twelve months [sec_mda · as of 2026-02-17].
- Nasdaq compliance risk — The company faces risks related to maintaining compliance with Nasdaq continued listing requirements [sec · filed 2025-10-06].
- Dependence on external financing — The company has historically relied on debt and equity issuances to fund operations and may need additional capital to continue [sec_mda · as of 2026-08-13].
- Commercialization and market acceptance — Strategic partnerships may not facilitate commercialization or market acceptance of the technology, and supply chain disruptions could impact operations [sec · filed 2025-10-06].
What to watch
- Ability to secure additional funding to address going concern and fund operations beyond twelve months [sec_mda · as of 2026-02-17].
- Progress of clinical trials and regulatory approvals for new products, including the Phase 3 study of GammaTile [catalyst_timeline].
- Revenue growth from commercial products (Evo, OneRF) and milestone payments from partnerships [sec_mda · as of 2026-08-13].
- Maintenance of Nasdaq listing compliance and any related disclosures [sec · filed 2025-10-06].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run NeuroOne Medical Technologies Corporation through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NeuroOne Medical Technologies Corporation facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
8.8 months
D/E 0.64 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~1919d
0 buys · 6 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$16
| Holder | Shares | Value |
|---|---|---|
| sbi securities co., ltd. | 20 | $16 |
Short Interest
as of May 12, 2026- % of float
- 0.3%
- Days to cover
- 0.6
- Shares short
- 27,795
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NMTC short interestGovernance
Frequently asked questions
What is the AI investment thesis for NeuroOne Medical Technologies Corporation?
NeuroOne Medical Technologies Corporation is a medical technology company developing and commercializing thin film electrode technology for brain-related conditions, pain management, and drug delivery, with a focus on diagnostic, ablation, and stimulation applications.
What is NeuroOne Medical Technologies Corporation's next catalyst?
NeuroOne Medical Technologies Corporation's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy " — expected December 1, 2031.
Who is the CEO of NeuroOne Medical Technologies Corporation?
Mr. David A. Rosa M.D. is the chief executive officer of NeuroOne Medical Technologies Corporation (NMTC).
Where is NeuroOne Medical Technologies Corporation headquartered?
NeuroOne Medical Technologies Corporation (NMTC) is headquartered in Eden Prairie, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.